Doxofylline ameliorates liver fibrosis by regulating the ferroptosis signaling pathway

Bibliographic Details
Title: Doxofylline ameliorates liver fibrosis by regulating the ferroptosis signaling pathway
Authors: Lenan Xu, Meiling Zhang, Junzhi Pan, Xiangwei Xu, Yawen Zhang, Xue Han, Lina Yin, Lingfeng Chen, Juan Ren, Jie Yu, Yanmei Zhang, Guang Liang, Yi Zhang
Source: Frontiers in Pharmacology, Vol 14 (2023)
Publisher Information: Frontiers Media S.A., 2023.
Publication Year: 2023
Collection: LCC:Therapeutics. Pharmacology
Subject Terms: liver fibrosis, doxofylline, hepatic stellate cells, ferroptosis, deferoxamine (DFO), Therapeutics. Pharmacology, RM1-950
More Details: Liver fibrosis, a compensatory repair response to chronic liver injury, is caused by various pathogenic factors, and hepatic stellate cell (HSC) activation and phenotypic transformation are regarded as key events in its progression. Ferroptosis, a novel form of programmed cell death, is also closely related to different pathological processes, including those associated with liver diseases. Here, we investigated the effect of doxofylline (DOX), a xanthine derivative with potent anti-inflammatory activity, on liver fibrosis as well as the associated mechanism. Our results indicated that in mice with CCl4-induced liver fibrosis, DOX attenuated hepatocellular injury and the levels of liver fibrosis indicators, inhibited the TGF-β/Smad signaling pathway, and significantly downregulated the expression of HSC activation markers, both in vitro and in vivo. Furthermore, inducing ferroptosis in activated HSCs was found to be critical for its anti-liver fibrosis effect. More importantly, ferroptosis inhibition using the specific inhibitor, deferoxamine (DFO) not only abolished DOX-induced ferroptosis, but also led to resistance to the anti-liver fibrosis effect of DOX in HSCs. In summary, our results showed an association between the protective effect of DOX against liver fibrosis and HSC ferroptosis. Thus, DOX may be a promising anti-hepatic fibrosis agent.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1663-9812
Relation: https://www.frontiersin.org/articles/10.3389/fphar.2023.1135366/full; https://doaj.org/toc/1663-9812
DOI: 10.3389/fphar.2023.1135366
Access URL: https://doaj.org/article/ac598d55245548938485c11b0199b3e9
Accession Number: edsdoj.598d55245548938485c11b0199b3e9
Database: Directory of Open Access Journals
More Details
ISSN:16639812
DOI:10.3389/fphar.2023.1135366
Published in:Frontiers in Pharmacology
Language:English